slider

Himmune

EMPOWERING
THE HUMAN IMMUNE SYSTEM
TO FIGHT CANCER
NEWS
  • STRATEGIC RESEARCH PARTNERSHIP

    11/05/2017

    Pierre Fabre and H-Immune announce strategic research partnership to develop potentially ground-breaking cancer immunotherapies.

    > Read all

  • H-IMMUNE A BENEFICIE DE 30 K€ DE LA PART DE MATWIN

    11/05/2017

    > Read all

  • COMMUNIQUE DE PRESSE

    11/05/2017

    GAL 9 : Nouvelle cible first-in class en immuno-oncologie.

    > Read all

ABOUT US

H-Immune is an early stage biopharmaceutical company engaged in the development of novel therapeutics for the treatment of cancer.

Utilizing an immunotherapeutic approach, the company is exploring the development of novel, fully human antibody-based blockade therapeutics in an effort to generate new immuno-oncology treatments.

IMG_0012
OUR SCIENCE

The tremendous increase in knowledge on how the human immune system functions has enabled a revolution in cancer therapeutics through enabling a first generation of immune check point blockades. Considered one of the most promising approaches, immune-oncology based therapeutic strategies are aimed at reactivating natural immune defenses against tumors.

our_science
partnering
PARTNERING

Scientific breakthroughs are almost always the product of collaboration and for this reason H-Immune places high value on partnering with companies and organizations whose strengths complement and augment our own.

CONTACT
US


We are located in the heart of Paris.

Feel free to contact us. We will make sure you receive an answer as soon as possible.

H-IMMUNE SAS
Pépinière Paris Santé Cochin
29, rue du Faubourg Saint Jacques,
75014 Paris, France

back to top